Health Technology Assessment in Europe Discussed in New Report Recently Published by MarketPublishers.com

15 Nov 2011 • by Natalie Aster

LONDON – Health Technology Assessment (HTA) is playing an increasingly important role today across a number of regions that feel a financial breakdown. HTA is vividly influencing reimbursement, and moreover it is having an impact on price and market access. With greater scrutiny over the clinical and financial value of drugs, medical devices and procedures, HTA is being widely accepted around the world.

New market research study “Health Technology Assessment (HTA): a European perspective” worked out by FirstWord examines the current state with HTA in Europe. It discusses its impact on reimbursement and pricing to market access and focuses on the experiences of five European countries. The history of HTA and the key agencies in each country are reviewed. The report also reveals the challenges and problems, pitfalls and the potential of a harmonized approach to HTA in Europe.

Report Details:

Title: Health Technology Assessment (HTA): a European perspective
Published: October, 2011
Pages: 48
Price: US$ 995

Reports Contents:

EXECUTIVE SUMMARY

HTA AND MARKET ACCESS
What is HTA?
How does HTA influence price, reimbursement and market access?
  HTA and price
  HTA and reimbursement
  HTA and market access

HTA IN EUROPE
Adoption of HTA in Europe
Germany and HTA
  History of HTA
  Key agencies
  Influence of HTA on pricing, reimbursement and market access
France and HTA
  History of HTA
  Key agencies
  Influence of HTA on pricing, reimbursement and market access
Italy and HTA
  History of HTA
  Key agencies
  Influence of HTA on pricing, reimbursement and market access
Spain and HTA
  History of HTA
  Key agencies
  Influence of HTA on pricing, reimbursement and market access
UK and HTA
  History of HTA
  Key agencies
  Influence of HTA on pricing, reimbursement and market access
European trends

KEY CHALLENGES FOR HTA ACROSS EUROPE
Building capability
Knowledge sharing
Unresolved differences
  Perspective
  Data that is acceptable to HTA agencies
  Methods for conducting HTA
  Process and governance
  Implementation

POTENTIALS AND PITFALLS OF EUROPEANISATION OF HTA
Common clinical assessment at the European level?
Closer links between regulatory approval and HTA?
  Changing data needs
  Changing EPARs
  Risk/benefit assessment
  Changing early engagement
Uncommon economic assessment?
Reality check

CONCLUSIONS